Hyperthermia treatment for solid tumors is a long-used, but poorly accepted method in clinical use.
Modulated electro-hyperthermia (mEHT, trade name: oncothermia®) changes the paradigm, introduces a
novel, cellularly selective and immunogenic cell-ruination. The mEHT method produces tumor-vaccination,
presenting the unharmed genetic information of cancer cells to immune cells [1]. The mEHT method is
approved in more than 30 countries. Its phase II/III clinical applications indicate a broad perspective.